I have been watching Moderna for a while since the Pandemic started.
I am looking to get in and trade the Descending Triangle patterns here. I will probably get in this morning.
| Stat | Value |
|---|---|
| PE | NA |
| EPS | -1.39 |
| Beta | NA |
| Dividend | NA |
| Profit Margin | 0.00% |
| Operating Margin | -485.03% |
| Avg Volume | 26.66M |
| Shares Outstanding | 394.59M |
| Float | 271.5M |
| % Held by Insiders | 23.94% |
| % Held by Institutions | 53.53% |
| Shares Short | 27.19M |
| Short % of Outstanding | 6.89% |
Positives:
- Earnings are forecast to grow 45.1% per year
- Return vs Industry: MRNA exceeded the US Biotechs industry which returned 30.6% over the past year.
- Return vs Market: MRNA exceeded the US Market which returned 17.1% over the past year.
- High Growth Earnings: MRNA's is expected to become profitable in the next 3 years.
- Revenue vs Market: MRNA's revenue (28.1% per year) is forecast to grow faster than the US market (9.4% per year).
- High Growth Revenue: MRNA's revenue (28.1% per year) is forecast to grow faster than 20% per year.
- Short Term Liabilities: MRNA's short term assets ($2.8B) exceed its short term liabilities ($161.6M).
- Long Term Liabilities: MRNA's short term assets ($2.8B) exceed its long term liabilities ($377.5M).
- Debt Level: MRNA is debt free.
- Reducing Debt: MRNA had no debt 5 years ago.
Negatives
- Quality Earnings: MRNA is currently unprofitable.
- Earnings vs Industry: MRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).